Cian Healthcare Faces Audit Hurdles Post-Insolvency

Cian Healthcare Limited reported a standalone net loss of ₹21.02 crore for the year ended March 31, 2026. Consolidated net loss stood at ₹23.29 crore for the same period.

Reader Takeaway: Company exits insolvency but faces audit concerns; subsidiary in distress.

What just happened

Cian Healthcare Limited announced its audited financial results for the fiscal year ending March 31, 2026. The company reported a standalone revenue from operations of ₹28.30 crore and a net loss after tax of ₹21.02 crore. On a consolidated basis, revenue was also ₹28.30 crore, with a net loss of ₹23.29 crore.

The statutory auditors issued a qualified opinion on both the standalone and consolidated financial statements. This indicates that the auditors were unable to obtain sufficient appropriate audit evidence to form an opinion on certain aspects of the financial reporting.

Why this matters

These qualified audit opinions raise significant concerns for investors. They suggest that the company's financial statements may not present a true and fair view due to issues identified by the auditors. The company is currently in a post-CIRP transition phase, meaning it is recovering from a corporate insolvency resolution process.

The backstory

Cian Healthcare Limited has recently emerged from a Corporate Insolvency Resolution Process (CIRP). This process typically involves restructuring the company's debts and operations. However, the qualified audit opinions suggest that substantial cleanup and stabilization are still required.

Furthermore, the company's wholly-owned subsidiary, Dr. Smith's Biotech Private Limited, is also undergoing CIRP. The audit report for this subsidiary contained a Disclaimer of Opinion, indicating even more severe limitations in verifying its financial status. Cian Healthcare has already provisioned ₹2.20 crore and written off ₹4.89 crore against its investment in this subsidiary.

What changes now

Investors need to monitor how the new management addresses the issues raised by the auditors. The company must work towards resolving the discrepancies in inventory valuation, GST reconciliation, and internal controls. The outcome of the subsidiary's insolvency proceedings will also be crucial.

Risks to watch

Key risks include the inability to adequately value inventory (a difference of ₹13.54 crore was noted), lack of documented internal financial controls, unreconciled GST input tax credits, and difficulties in verifying trade receivables and advances, leading to significant expected credit loss provisions of ₹29.17 crore.

Peer comparison

(No peer comparison data available in the provided filing.)

Context metrics (time-bound)

• Revenue (FY26 Standalone/Consolidated): ₹28.30 crore
• Net Loss (FY26 Standalone): ₹21.02 crore
• Net Loss (FY26 Consolidated): ₹23.29 crore
• Total Assets (FY26 Standalone): ₹48.22 crore
• Total Assets (FY26 Consolidated): ₹61.55 crore
• Inventory Valuation Discrepancy: ₹13.54 crore
• Expected Credit Loss Provision (Trade Receivables/Advances): ₹29.17 crore
• Investment Written Off in Subsidiary: ₹4.89 crore

What to track next

Investors should closely watch future quarterly results, management commentary on addressing audit qualifications, and updates on the subsidiary's CIRP.